Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Hong Kong Stock Exchange  >  CanSino Biologics Inc.    6185   CNE100003F01

CANSINO BIOLOGICS INC.

(6185)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryAll NewsPress ReleasesOfficial PublicationsSector news

CanSino's COVID-19 vaccine candidate approved for military use in China

share with twitter share with LinkedIn share with facebook
06/29/2020 | 02:09am EDT
FILE PHOTO: Small bottles labeled with

China's military has received the greenlight to use a COVID-19 vaccine candidate developed by its research unit and CanSino Biologics after clinical trials proved it was safe and showed some efficacy, the company said on Monday.

The Ad5-nCoV is one of China's eight vaccine candidates approved for human trials at home and abroad for the respiratory disease caused by the new coronavirus. The shot also won approval for human testing in Canada.

China's Central Military Commission approved the use of the vaccine by the military on June 25 for a period of one year, CanSino said in a filing. The vaccine candidate was developed jointly by CanSino and a research institute at the Academy of Military Science (AMS).

"The Ad5-nCoV is currently limited to military use only and its use cannot be expanded to a broader vaccination range without the approval of the Logistics Support Department," CanSino said, referring to the Central Military Commission department which approved the military use of the vaccine.

CanSino declined to disclose whether the innoculation of the vaccine candidate is mandatory or optional, citing commercial secrets, in an email to Reuters.

The military approval follows China's decision earlier this month to offer two other vaccine candidates to employees at state-owned firms travelling overseas.

The Phase 1 and 2 clinical trials of the CanSino's vaccine candidate showed it has the potential to prevent diseases caused by the coronavirus, which has killed half a million people globally, but its commercial success cannot be guaranteed, the company said.

Separately, AMS received an approval earlier this month to test its second experimental coronavirus vaccine in humans.

No vaccine has yet been approved for commercial use against the illness caused by the new coronavirus, but over a dozen vaccines from more than 100 candidates globally are being tested in humans.

(Reporting by Roxanne Liu and Ryan Woo; Editing by Miyoung Kim and Ana Nicolaci da Costa)

share with twitter share with LinkedIn share with facebook
All news about CANSINO BIOLOGICS INC.
09/22Pakistan launches Phase III trials for Chinese Cansinobio's COVID-19 vaccine
RE
09/21CANSINO BIOLOGICS : Notice of the 2020 first extraordinary general meeting
PU
09/21CANSINO BIOLOGICS : (1) change in use of the remaining unutilized proceeds recei..
PU
09/21CANSINO BIOLOGICS : Form of Proxy for use at the 2020 First Extraordinary Genera..
PU
09/18CANSINO BIOLOGICS : Chinese researchers to test double doses of CanSino's corona..
RE
09/16CANSINO BIOLOGICS : Turkey begins Phase III trials of Chinese coronavirus vaccin..
RE
09/15CANSINO BIOLOGICS : In coronavirus vaccine race, China inoculates thousands befo..
RE
09/15FACTBOX : The race for a coronavirus vaccine
RE
09/14REFILE-China coronavirus vaccine may be ready for public in November - offici..
RE
09/09CANSINO BIOLOGICS : Phase 3 COVID-19 vaccine trial in Pakistan expected to begin..
RE
More news
Financials
Sales 2020 274 M 40,3 M 40,3 M
Net income 2020 -109 M -16,0 M -16,0 M
Net cash 2020 2 018 M 296 M 296 M
P/E ratio 2020 -5 281x
Yield 2020 -
Capitalization 56 383 M 8 272 M 8 273 M
EV / Sales 2020 198x
EV / Sales 2021 82,8x
Nbr of Employees 429
Free-Float 37,1%
Chart CANSINO BIOLOGICS INC.
Duration : Period :
CanSino Biologics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CANSINO BIOLOGICS INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 158,64 CNY
Last Close Price 139,94 CNY
Spread / Highest target 55,3%
Spread / Average Target 13,4%
Spread / Lowest Target -65,1%
EPS Revisions
Managers
NameTitle
Xue Feng Yu Chairman, Chief Executive Officer & GM
Jiang Feng Li Chairman-Supervisory Board
Shou Bai Chao COO, Executive Director & Deputy General Manager
Jing Wang Chief Financial Officer & Board Secretary
Tao Zhu Executive Director, CSO & Deputy General Manager
Sector and Competitors
1st jan.Capitalization (M$)
CANSINO BIOLOGICS INC.169.89%8 701
CSL LIMITED7.17%94 731
BIOGEN INC.-4.95%44 650
SAMSUNG BIOLOGICS CO.,LTD.59.35%38 784
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.171.85%32 218
WUXI BIOLOGICS (CAYMAN) INC.87.33%32 020